2. Signaling Pathways
  3. Apoptosis
  4. RIP kinase

RIP kinase

Receptor-interacting protein kinases; RIPK

RIP kinase

Related Products

PDF 0.22 MB

Receptor-interacting protein (RIP) kinases are a group of threonine/serine protein kinases with a relatively conserved kinase domain but distinct non-kinase regions. There are seven members of the RIPK family, RIPK1-7, some of which have emerged as critical effectors of immunity to infection with a diverse array of bacterial, viral, and protozoal pathogens.

RIP kinases are cellular signaling molecules that are critical for homeostatic signaling in both communicable and non-communicable disease processes. RIPK1, RIPK2, RIPK3 and RIPK7 have emerged as key mediators of intracellular signal transduction including inflammation, autophagy and programmed cell death, and are thus essential for the early control of many diverse pathogenic organisms.

RIP kinase Isoform Specific Products:

RIP kinase Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-146758
    RIPK1-IN-14
    		Inhibitor
    RIPK1-IN-14 (Compound 41) is a potent inhibitor of RIPK1 with an IC50 value of 92 nM. RIPK1-IN-14 shows a significant anti-necroptotic effect in a necroptosis model in U937 cells.
    RIPK1-IN-14
  • HY-124643
    RIPK2-IN-3
    		Inhibitor
    RIPK2-IN-3 (FCG806791773) is a RIPK2 inhibitor. RIPK2-IN-3 inhibits recombinant truncated RIPK2 with an IC50 of 6.39 μM. RIPK2-IN-3 can be used for research of inflammation and cancer.
    RIPK2-IN-3
  • HY-155151
    RIPK2/3-IN-1
    		Inhibitor
    RIPK2/3-IN-1 is a potent dual RIPK2/3 kinases inhibitor with IC50 values of 3 nM and 117 nM, respectively. RIPK2/3-IN-1 is against RIPK2 with IC50 value 14 nM in 14-TriLAN-Gly/NOD1 THP-1 cell-based NF-κB reporter assay.
    RIPK2/3-IN-1
  • HY-149052
    SZM-1209
    		Inhibitor
    SZM-1209 is an orally active, potent and specific RIPK1 inhibitor, with a Kd of 85 nM. SZM-1209 exhibits high anti-necroptotic activity (EC50=22.4 ± 8.1 nM). SZM-1209 shows anti-SIRS (systemic inflammatory response syndrome), and anti-ALI (acute lung injury) effects.
    SZM-1209
  • HY-114573
    TNF-α-IN-19
    		Inhibitor
    TNF-α-IN-19 is an inhibitor of TNFα that can block the interaction between TNFαRI, TRADD, and RIP1, the EC50 values for TNFα, IL-1β, and IL-1β/TNFα are 2.451, 3.792 and 1.54 μM, respectively. TNF-α-IN-19 only inhibits the degradation of IκBα when cells are stimulated by TNFα and not by IL-1β.
    TNF-α-IN-19
  • HY-156368
    RIPK3-IN-4
    		Inhibitor
    RIPK3-IN-4 (Compound 42) is a RIPK3 inhibitor. RIPK3-IN-4 inhibits HK-2 cell damage, necroptosis and inflammatory responses. RIPK3-IN-4 reduces Cisplatin (HY-17394)- and I/R-induced kidney damage, inflammatory response and necroptosis in acute kidney injury.
    RIPK3-IN-4
  • HY-162237
    RIPK1-IN-22
    		Inhibitor
    RIPK1-IN-13 (compound 28) is a selective inhibitor for receptor-interacting serine/threonine-protein kinase 1 (RIPK1), the inhibitory activity is measured by ADP-Glo Kinase Assay with a pKi of 7.66. RIPK1-IN-13 inhibits human leukaemia cells U937 with a pIC50 of 7.2.
    RIPK1-IN-22
  • HY-153436
    RIP1 kinase inhibitor 6
    		Inhibitor
    RIP1 kinase inhibitor 6 is a potent and selective RIP1 kinase inhibitor with an IC50 of < 100 nM in human R1P1 kinase assay. RIP1 kinase inhibitor 6 is extracted from patent WO2020103884, example 80.
    RIP1 kinase inhibitor 6
  • HY-157751
    RIPK1-IN-21
    		Inhibitor
    RIPK1-IN-21 (Compound I-5) is an inhibitor of RIPK1 with an EC50 value of 14.8 nM. RIPK1-IN-21 can be used in the research of neurodegenerative, autoimmune, and inflammatory diseases.
    RIPK1-IN-21
  • HY-158334
    NDs-IN-1
    		Inhibitor
    (Neurodegenerative diseases) NDs-IN-1 (Compound 3g) inhibits the activities of key enzymes such as hBACE-1, hAChE and hMAO-B. NDs-IN-1 is a novel non-covalent multi-target inhibitor. NDs-IN-1 is mainly used in the study of neurodegenerative diseases.
    NDs-IN-1
  • HY-163390
    RIP1 kinase inhibitor 9
    		Inhibitor
    RIP1 kinase inhibitor 9 (compound SY-1) is a selective RIP kinase inhibitor. RIP1 kinase inhibitor 9 effectively suppresses the central inflammatory response induced by epilepsy. RIP1 kinase inhibitor 9 inhibits Z-VAD-FMK (HY-16658B)-induced necroptosis in HT-29 cells with an EC50 of 7.04 nM.
    RIP1 kinase inhibitor 9
  • HY-168640
    RIP3 activator 1
    		Activator
    RIP3 activator 1 (compound C8) is a potent RIP3 activator. RIP3 activator 1 inhibits cell growth. RIP3 activator 1 induces necroptosis through the RIP3/p62/Keap1 signaling pathway. RIP3 activator 1 increases the protein expression of p-MLKL. RIP3 activator 1 induces autophagy. RIP3 activator 1 increases accumulation of LC3-II and p62 protein expression.
    RIP3 activator 1
  • HY-157456
    RIPK1-IN-19
    		Inhibitor ≥98.0%
    RIPK1-IN-19 (compound 10b) is a selective RIPK1 inhibitor (IC50=15 nM). RIPK1-IN-19 displays potent protective activity in TNFα-induced systemic inflammatory response syndrome (SIRS) model and Imiquimod (IMQ)-induced psoriasis model. RIPK1-IN-19 can be used in research on inflammation and immune system diseases.
    RIPK1-IN-19
  • HY-146694
    RIPK2-IN-1
    		Inhibitor
    RIPK2-IN-1 (compound 18f) is a potent RIPK2 inhibitor with an IC50 of 51 nM. RIPK2-IN-1 inhibits ALK2 with an IC50 of 5 nM. RIPK2-IN-1 has an IC50 of 390 nM on RIPK2/NOD2 in cell assay.
    RIPK2-IN-1
  • HY-143480
    RIPK1-IN-15
    		Inhibitor
    RIPK1-IN-15 (Compound 2.5) is a potent inhibitor of RIPK1. RIPK1-IN-15 has the potential for the research neurodegenerative, autoimmune, and inflammatory diseases.
    RIPK1-IN-15
  • HY-19628A
    OD36 hydrochloride
    		Inhibitor
    OD36hydrochloride is a RIPK2 inhibitor with an IC50 of 5.3 nM. OD36 hydrochloride is a macrocyclic inhibitor with potent binding to the ALK2 kinase ATP pocket. OD36 hydrochloride shows ALK2-directed activity with KDs of 37 nM.
    OD36 hydrochloride
  • HY-147235
    RIPK2-IN-2
    		Inhibitor
    RIPK2-IN-2 (example 25) is a RIP2 kinase PROTAC inhibitor. RIPK2-IN-2 can block RIP2-dependent proinflammatory signaling, regulated RIP2 kinase activity in auto inflammatory diseases.
    RIPK2-IN-2
  • HY-168116
    RIPK1-IN-27
    		Inhibitor
    RIPK1-IN-27 (compund 19) is a RIPK1 inhibitor.
    RIPK1-IN-27
  • HY-160216A
    RIPK1-IN-18 sulfate hydrate
    		Inhibitor
    RIPK1-IN-18 sulfate hydrate is a potent RIPK1 inhibitor that can be used in autoimmune diseases research (NZ748385A; compound i).
    RIPK1-IN-18 sulfate hydrate
  • HY-157309
    RIPK2-IN-4
    		Inhibitor
    RIPK2-IN-4 is a potent and specific RIPK2 inhibitor with an IC50 value of 5 nM.
    RIPK2-IN-4
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
RIP kinase Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.